The Zuckerberg Chan Biohub is committing $500 million over five years to build AI-powered simulations of the human body, partnering with Nvidia and top research institutions in an ambitious push to ultimately cure all human disease.
OpenAI launches GPT-5.5 with record-breaking agentic performance and free healthcare access, Google unveils a full enterprise AI stack with $750M in startup funding, and Moonshot's Kimi K2.6 challenges top models at a fraction of the cost, signaling an intensifying race to dominate the AI industry.
OpenAI launches GPT-Rosalind, a restricted life sciences AI model that outperforms 95% of human experts in RNA sequence prediction and surpasses other AI on science benchmarks, with access limited to approved organizations like Amgen and Moderna due to misuse concerns.
OpenAI launches GPT-Rosalind, a frontier AI model purpose-built for life sciences that outperforms human experts above the 95th percentile on RNA sequence-to-function tasks, beats competitors on key benchmarks, and is now available in research preview for U.S. Enterprise customers through partnerships with Amgen, Moderna, and the Allen Institute.
AWS launches Amazon Bio Discovery, an AI-powered platform that designed nearly 300,000 novel antibody molecules in collaboration with Memorial Sloan Kettering Cancer Center, slashing drug discovery timelines from up to a year down to just weeks.
AI is going deeply personal this week: Utah launches a pilot letting AI renew psychiatric prescriptions for just $19/month, OpenAI secures a record $122 billion funding round at an $852 billion valuation, and thousands of workers worldwide are filming their daily chores to train the next generation of humanoid robots.
California becomes the first state to approve an AI app to prescribe psychiatric medications without human oversight, as San Francisco startup Legion Health receives clearance from the state's medical board, sparking both excitement and serious concern from experts over algorithm-driven mental health treatment.
Anthropic acquires stealth AI biotech startup Coefficient Bio in a $400 million stock deal, bringing the 10-person team behind an AI-driven drug discovery platform into its health and life sciences division, accelerating the company's growing push into healthcare.
Kintsugi, a California startup that spent seven years developing AI software to detect depression and anxiety from speech patterns, is shutting down and open-sourcing its technology after FDA regulatory delays drained its funding before approval could be secured.
Google launches a sweeping global Gemini AI expansion, supercharging Search, Maps, Workspace, Fitbit, and health education with powerful new features including conversational map queries, personalized recommendations, and a $10 million commitment to AI-driven clinician training.